Baseline characteristics identifying patients (pts) with multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel; bb2121) who are at risk for severe/refractory inflammatory adverse events (iAEs)

被引：0
|
作者：
Mashadi-Hossein, Afshin
Rytlewski, Julie
Shamsuzzaman, Md
Basudhar, Debashree
Takhar, Mandeep
Kostic, Ana
Campbell, Timothy Brandon
Manier, Salomon
Lin, Yi
Martin, Nathan
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
[2] Lille Univ Hosp, Lille, France
[3] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20005
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Minakata, Daisuke
    Ishida, Tadao
    Ando, Kiyoshi
    Suzuki, Rikio
    Tanaka, Junji
    Hagiwara, Shotaro
    Ananthakrishnan, Revathi
    Kuwayama, Shigeki
    Nishio, Mitsufumi
    Kanda, Yoshinobu
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (05) : 729 - 737
  • [2] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
    Daisuke Minakata
    Tadao Ishida
    Kiyoshi Ando
    Rikio Suzuki
    Junji Tanaka
    Shotaro Hagiwara
    Revathi Ananthakrishnan
    Shigeki Kuwayama
    Mitsufumi Nishio
    Yoshinobu Kanda
    Kenshi Suzuki
    International Journal of Hematology, 2023, 117 : 729 - 737
  • [3] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
    Einsele, Hermann
    Berdeja, Jesus
    Raje, Noopur
    Siegel, David
    Lin, Yi
    Anderson, Larry, Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy
    Jagannath, Sundar
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
  • [4] Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis
    Einsele, H.
    Berdeja, J.
    Raje, N. S.
    Siegel, D. S.
    Lin, Y.
    Anderson, L. D., Jr.
    Rodriguez-Otero, P.
    Manier, S.
    Cavo, M.
    Truppel-Hartmann, A.
    Rowe, E.
    Sanford, J.
    Wang, J.
    Campbell, T. B.
    Jagannath, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 198 - 199
  • [5] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
    Raje, Noopur S.
    Siegel, David S.
    Jagannath, Sundar
    Lonial, Sagar
    Munshi, Nikhil C.
    Moreau, Philippe
    Goldschmidt, Hartmut
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Huang, Liping
    Agarwal, Amit
    Wang, Julie
    Campbell, Timothy B.
    San-Miguel, Jesus F.
    Reece, Donna E.
    BLOOD, 2020, 136
  • [6] KARMMA STUDY: CHARACTERIZATION OF CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS (PTS) WITH MULTIPLE RELAPSE/REFRACTORY MYELOMA (MMRR) TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121)
    Albert, Oriol
    Ankit, Kansagra
    Yi, Lin
    Jesus, Berdeja
    Nina, Shah
    Ibrahim, Yakoub-Agha
    Hermann, Einsele
    Alessandro, Rambaldi
    Anna, Truppel-Hartmann
    Everton, Rowe
    Julie, Wang
    Amit, Agarwal
    Timothy, Campbell B.
    Sagar, Lonial
    HAEMATOLOGICA, 2021, 106 (10) : 77 - 78
  • [7] Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma
    Kansagra, Ankit
    Lin, Yi
    Berdeja, Jesus G.
    Shah, Nina
    Oriol, Albert
    Yakoub-Agha, Ibrahim
    Einsele, Hermann
    Rambaldi, Alessandro
    Truppel-Hartmann, Anna
    Rowe, Everton
    Wang, Julie
    Agarwal, Amit
    Campbell, Timothy B.
    Lonial, Sagar
    BLOOD, 2020, 136
  • [8] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
    Berdeja, Jesus G.
    Raje, Noopur S.
    Siegel, David S.
    Lin, Yi
    Anderson, Larry D., Jr.
    Rodriguez-Otero, Paula
    Manier, Salomon
    Einsele, Hermann
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Sanford, Jill
    Wang, Julie
    Campbell, Timothy B.
    Jagannath, Sundar
    BLOOD, 2020, 136
  • [9] KarMMa study: Characterization of Cytokine Release Syndrome (CRS) in patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with Idecabtagene Vicleucel (ide-cel, bb2121)
    Einsele, H.
    Kansagra, A.
    Lin, Y.
    Berdeja, J.
    Shah, N.
    Oriol, A.
    Yakoub-Agha, I
    Rambaldi, A.
    Truppel-Hartmann, A.
    Rowe, E.
    Wang, J.
    Agarwal, A.
    Campbell, T. B.
    Lonial, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 208 - 209
  • [10] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma in the pivotal phase 2 KarMMa study
    Weisel, K.
    Manier, S.
    Kansagra, A.
    Anderson, Jr L. D.
    Berdeja, J.
    Jagannath, S.
    Lin, Y.
    Lonial, S.
    Shah, N.
    Raje, N.
    Siegel, D.
    Oriol, A.
    Truppel-Hartmann, A.
    Rowe, E.
    Patel, P.
    Agarwal, A.
    Campbell, T. B.
    Rodriguez-Otero, P.
    Munshi, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 179 - 180
12345